Welcome to our dedicated page for Medicus Pharma news (Ticker: MDCX), a resource for investors and traders seeking the latest updates and insights on Medicus Pharma stock.
Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech and life sciences company whose news flow centers on clinical trial progress, regulatory milestones, strategic collaborations and capital markets activity. The company describes itself as a precision guided biotech/life sciences organization focused on advancing SkinJect™, an investigational microneedle therapy for basal cell carcinoma (BCC) of the skin, and Teverelix, a long-acting GnRH antagonist for hormone-driven conditions.
News updates frequently cover the SkinJect™ program, including Phase 2 study SKNJCT-003 in the United States, regulatory and ethics approvals to expand into the United Kingdom, and SKNJCT-004 in the United Arab Emirates. Releases also highlight interactions with the U.S. Food and Drug Administration (FDA), such as Type C meeting feedback supporting a 505(b)(2) regulatory pathway and the filing of an FDA Commissioner’s National Priority Voucher (CNPV) application for SKNJCT-003.
Another major theme in MDCX news is the Teverelix pipeline, added through the acquisition of Antev Limited. Company communications describe prior Phase 1 and Phase 2a data, FDA guidance on Phase 3 design, and plans to use AI-enabled analytics—via an engagement with Reliant AI Inc.—to support upcoming Teverelix clinical studies. Additional coverage includes Phase 1 data in healthy female volunteers and acceptance of Teverelix research for presentation at a leading endocrinology conference.
Investors following MDCX news will also see announcements on collaborations, such as the Gorlin Syndrome Alliance partnership for compassionate access to SkinJect™ and a non-binding memorandum of understanding with Helix Nanotechnologies, Inc. around thermostable infectious disease vaccines. Capital markets updates, including warrant inducement agreements, standby equity purchase activity and debenture financings, are disclosed through press releases and Form 8-K filings.
This news page aggregates these developments so readers can review Medicus Pharma’s clinical, regulatory, partnering and financing announcements in one place.
Medicus Pharma (NASDAQ: MDCX) announced a collaboration with Swanielle to expand its Phase 2 clinical study for Basal Cell Carcinoma (BCC) treatment in the Asia-Pacific region. The ongoing Phase 2 study (SKNJCT-003) has already enrolled 25% of the targeted 60 patients across nine U.S. clinical sites. The company plans an interim data analysis in Q1 2025 and FDA Type C meeting in Q2 2025. The study evaluates two dose levels of D-MNA against placebo, building on successful Phase 1 results that showed complete responses in 6 participants with no serious adverse events.
Medicus Pharma announces key leadership changes with the appointment of Faisal Mehmud, MD as Chief Medical Officer and the promotion of Edward Brennan, MD to Chief Scientific Officer & Head of R&D. Dr. Mehmud brings over 20 years of global pharmaceutical experience from companies like GSK, Pfizer, and BMS. The company is developing a novel dissolvable doxorubicin-containing microneedle array (D-MNA) to treat non-melanoma skin cancer. Their Phase 1 study completed in March 2021 showed safety and tolerability, with six participants achieving complete response. A Phase 2 clinical trial is currently recruiting 60 patients across nine U.S. sites to evaluate two dose levels against placebo.
Medicus Pharma (NASDAQ: MDCX) announced the closing of its US$4.0M initial public offering in the United States, consisting of 970,000 units at US$4.125 per unit. Each unit includes one common share and one warrant with a US$4.64 exercise price, expiring in 5 years. The company's shares and warrants began trading on Nasdaq under 'MDCX' and 'MDCXW'. The proceeds will fund Phase 2 clinical trials for basal cell carcinoma treatment using their doxorubicin microarray needle skinpatch, with potential expansion to other non-melanoma skin diseases. The underwriter exercised an overallotment option for 145,500 additional warrants.